Special Authority applications approved for emtricitabine with tenofovir disoproxil in 2022

Thank you for your request dated 1 November 2022 under the Official Information Act 1982 (OIA) for information relating to funded access for emtricitabine with tenofovir disoproxil approved specifically via Special Authority (SA) form 2138(external link). You requested:

The number of applications for initial application/renewal for Tenofovir Disoproxil/Emtricitabine under the special authority form SA2138 between 1 July 2022 and 31 Oct 2022

I am pleased to provide the data requested within the table below.

Table: Special Authority applications approved for emtricitabine with tenofovir disoproxil via SA2138 between 1 July 2022 and 31 Oct 2022

Notes

• The data provided is a count of distinct Special Authority applications approved for the use of emtricitabine with tenofovir disoproxil via SA2138.
• These figures represent the number of approved applications. They do not represent the number of people actually dispensed the relevant medicine in a given period.
• If a person has had more than one relevant Special Authority approval, they will be counted more than once in this data.
• The monthly figures are counted based on the month the Special Authority application was submitted, not approved.
• The data for October 2022 may not be complete, and is subject to change, as there is a delay between Special Authority applications being made and application data becoming available to Pharmac.

We trust that this information answers your queries. We are making our information more freely available, so we now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.